Trial · NCT00194896
Preferred Treatment of Type 1.5 Diabetes
NCT00194896, Not applicable, Completed, University of Washington; results first posted 2011-08-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Preferred Treatment of Type 1.5 Diabetes. Trials, record NCT00194896. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00194896
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Preferred Treatment of Type 1.5 Diabetes
- NCT number
- NCT00194896
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 64 participants, actual
- Lead sponsor
- University of Washington
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- rosiglitazone, glyburide
- First posted
- 2005-09-19
- Last updated
- 2018-03-29
- Results first posted
- 2011-08-10
- Limitations and caveats
- Small numbers based on high drop out of participants.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months. | 36 months | Changes in beta cell function assessed by fasting and stimulated C-peptide measured at 36 months. |
| Secondary | Patients Positive for T Cell Responses to Islet Proteins at 36 Months. | 36 months | Number of participants positive for T cell reactivity to islet proteins at 36 months. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months. | 36 months | Analysis per protocol | ng per ml | MEAN |
| SECONDARY | Patients Positive for T Cell Responses to Islet Proteins at 36 Months. | 36 months | participants | NUMBER |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months. | Rosiglitazone Autoantibody Positive | Fasting C-peptide | -0.4 | Standard Deviation 1.0 | ng per ml |
| Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months. | Rosiglitazone Autoantibody Negative | Fasting C-peptide | -1.4 | Standard Deviation 1.6 | ng per ml |
| Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months. | Glyburide Autoantibody Positive | Fasting C-peptide | 0.1 | Standard Deviation 1.2 | ng per ml |
| Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months. | Glyburide Autoantibody Negative | Fasting C-peptide | 0.3 | Standard Deviation 1.1 | ng per ml |
| Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months. | Rosiglitazone Autoantibody Positive | Glucagon Stimulated C-peptide | -0.6 | Standard Deviation 1.6 | ng per ml |
| Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months. | Rosiglitazone Autoantibody Negative | Glucagon Stimulated C-peptide | -2.8 | Standard Deviation 2.5 | ng per ml |
| Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months. | Glyburide Autoantibody Positive | Glucagon Stimulated C-peptide | 3.1 | Standard Deviation 12.1 | ng per ml |
| Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months. | Glyburide Autoantibody Negative | Glucagon Stimulated C-peptide | 0.3 | Standard Deviation 2.2 | ng per ml |
| Patients Positive for T Cell Responses to Islet Proteins at 36 Months. | Rosiglitazone Autoantibody Positive | 1 | 0 | participants | |
| Patients Positive for T Cell Responses to Islet Proteins at 36 Months. | Rosiglitazone Autoantibody Negative | 2 | 0 | participants |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Rosiglitazone Autoantibody Positive | 15 | |
| Overall Study | STARTED | Rosiglitazone Autoantibody Negative | 15 | |
| Overall Study | STARTED | Glyburide Autoantibody Positive | 13 | |
| Overall Study | STARTED | Glyburide Autoantibody Negative | 21 | |
| Overall Study | COMPLETED | Rosiglitazone Autoantibody Positive | 4 | |
| Overall Study | COMPLETED | Rosiglitazone Autoantibody Negative | 10 | |
| Overall Study | COMPLETED | Glyburide Autoantibody Positive | 7 | |
| Overall Study | COMPLETED | Glyburide Autoantibody Negative | 9 | |
| Overall Study | NOT COMPLETED | Rosiglitazone Autoantibody Positive | 11 | |
| Overall Study | NOT COMPLETED | Rosiglitazone Autoantibody Negative | 5 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events24
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypoglycemia | Endocrine disorders | Rosiglitazone Autoantibody Positive | 0 | 15 | 0 |
| other | Hypoglycemia | Endocrine disorders | Rosiglitazone Autoantibody Negative | 0 | 15 | 0 |
| other | Hypoglycemia | Endocrine disorders | Glyburide Autoantibody Positive | 1 | 13 | 1 |
| other | Hypoglycemia | Endocrine disorders | Glyburide Autoantibody Negative | 1 | 21 | 1 |
| serious | Death | General disorders | Rosiglitazone Autoantibody Positive | 1 | 15 | 1 |
| serious | Death | General disorders | Rosiglitazone Autoantibody Negative | 0 | 15 | 0 |
| serious | Death | General disorders | Glyburide Autoantibody Positive | 0 | 13 | 0 |
| serious | Death | General disorders | Glyburide Autoantibody Negative | 0 | 21 | 0 |
| serious | Cholecystitis | Endocrine disorders | Rosiglitazone Autoantibody Positive | 0 | 15 | 0 |
| serious | Cholecystitis | Endocrine disorders | Rosiglitazone Autoantibody Negative | 1 | 15 | 1 |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 adverse eventsAdverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Rosiglitazone Autoantibody Positive | ||
| Total, all-cause mortality | Rosiglitazone Autoantibody Negative | ||
| Total, all-cause mortality | Glyburide Autoantibody Positive | ||
| Total, all-cause mortality | Glyburide Autoantibody Negative | ||
| Total, other adverse events | Rosiglitazone Autoantibody Positive | 0 | 15 |
| Total, other adverse events | Rosiglitazone Autoantibody Negative | 0 | 15 |
| Total, other adverse events | Glyburide Autoantibody Positive | 1 | 13 |
| Total, other adverse events | Glyburide Autoantibody Negative | 1 | 21 |
| Total, serious adverse events | Rosiglitazone Autoantibody Positive | 1 | 15 |
| Total, serious adverse events | Rosiglitazone Autoantibody Negative | 2 | 15 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers35
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00194896
GET https://conductscience.org/api/trials/v1/NCT00194896/events?page=2